Iniparib

Search with Google Search with Bing

Information
Drug Name
Iniparib
Description
Entry(CIViC)
1
CIViC
Disease Mutation EL ET ED CS VO TR Pubmed Links
pancreatic cancer BRCA2 LOSS-OF-FUNCTION BRCA2 LOSS-OF-FUNCTION C Predictive Supports Sensitivity/Response Rare Germline 3 21508395 Detail
Annotation
Description Associated Genes Associated Variants Sensitivity Supported Source Links
Patient with germline BRCA2 mutation underwent res... BRCA2 BRCA2 LOSS-OF-FUNCTION BRCA2 LOSS-OF-FUNCTION Sensitivity true CIViC Evidence detail
NCT ID Status Phase Summary Start date Completion date
NCT01045304 Completed Phase 2 Study of SAR240550 (BSI-201) in Combination With Gemcitabine/Carboplatin, in Patients With Metastatic Triple Negative Breast Cancer February 2010 November 2012
NCT00677079 Completed Phase 2 Single Arm Study of BSI-201 in Patients With BRCA-1 or BRCA-2 Associated Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer June 2008 December 2008
NCT00938652 Completed Phase 3 A Phase 3, Multi-Center Study of Gemcitabine/Carboplatin, With or Without BSI-201, in Patients With ER-, PR-, and Her2-Negative Metastatic Breast Cancer July 2009 February 2012
NCT00540358 Completed Phase 2 A Phase 2 Trial of Standard Chemotherapy, With or Without BSI-201, in Patients With Triple Negative Metastatic Breast Cancer October 2007 June 2010
NCT01086254 Completed Phase 2 SAR240550 in Combination With Gemcitabine/Cisplatin in Non-small Cell Lung Cancer May 2010 December 2011
NCT01161836 Completed Phase 1 An Open-label Study Investigating the Disposition and QT/QTc Interval Effects of 400 mg [14C]-Iniparib(3.7 MBq, 100 µCi) July 2010 June 2011
NCT01130259 No longer available An Open-Label, Expanded Access Protocol of Iniparib Breast Cancer